G protein subunit beta 4Genealiases: CMTD1F · HG2B
Q-omics provides the consensus-scored GNB4 profile across patient tissues and cancer cell-line models. GNB4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GNB4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, GNB4 protein abundance shows 28,296 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, KIRC, and PDAC as cancer lineages where GNB4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNB4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNB4 survival associations across molecular data types. GNB4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNB4 RNA expression–survival associations across cancer types. High GNB4 expression shows unfavorable associations in BLCA, KIRP, STAD, ACC and OV, but favorable associations in CHOL. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for GNB4 RNA expression.
This table summarizes GNB4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GNB4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNB4 shows lower tumor expression in LUAD, KICH and UCEC and higher tumor expression in KIRC, HNSC and BRCA. The KIRC box plot shows higher GNB4 RNA expression in tumor versus normal tissue (log2 FC = +1.170, t-test p < 0.001).
This table shows molecular features associated with GNB4 in patient tissues and cancer cell lines. In patient samples, GNB4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, GNB4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and OESOPHAGUS.
